Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatm…
An institutional-grade, numbers-driven thesis on PRTA — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 16, 2026, TradersQuant's model rates Prothena Corporation plc (PRTA) 56/100 with a 12-month base-case forecast of $24.50 — +176.5% versus the current price of $8.86. Prothena Corporation plc trades at $8.86 in the Healthcare sector, with a market capitalisation of $463.8M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for PRTA is $24.50, implying +176.5% versus the current price. The model's 12-month scenario range runs from $5.29 (bear) to $6.89 (bull), with a base case of $5.87.
On the fundamentals, Prothena Corporation shows a P/E of -10.7, trailing revenue of $9.7M, revenue growth of -92.8% YoY. This page also tracks PRTA's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
PRTA currently carries a TradersQuant composite score of 56/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $24.50 implies +176.5% from $8.86. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for PRTA is $24.50, about +176.5% versus the latest price of $8.86. Consensus is based on 28 analysts.
TradersQuant's 12-month model forecast for PRTA is a base case of $5.87, ranging from $5.29 (bear) to $6.89 (bull), an expected return of -33.7%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for PRTA over the next 12 months is $5.87 in the base case (bear $5.29, bull $6.89), versus today's price of $8.86. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for PRTA — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates PRTA's fair value at $24.50, implying +176.5% of expected upside versus the current price.
Prothena Corporation does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
